Leukemia Clinical Trial
— Interfant06Official title:
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia
NCT number | NCT00550992 |
Other study ID # | CDR0000570260 |
Secondary ID | DCOG-INTERFANT-0 |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2006 |
Verified date | February 2019 |
Source | Dutch Childhood Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of
cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem
cells. When the healthy stem cells from a donor are infused into the patient they may help
the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Sometimes the transplanted cells from a donor can make an immune response against the body's
normal cells. Giving cyclosporine, methotrexate, leucovorin, and antithymocyte globulin
before and after transplant may stop this from happening. It is not yet known which treatment
regimen is most effective in treating acute leukemia.
PURPOSE: This randomized clinical trial is studying how well different therapies work in
treating infants with newly diagnosed acute leukemia.
Status | Recruiting |
Enrollment | 445 |
Est. completion date | |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 1 Year |
Eligibility |
DISEASE CHARACTERISTICS: Inclusion criteria: - Diagnosis of acute lymphoblastic leukemia (ALL) or biphenotypic leukemia meeting the following criteria: - Based on European Group for the Classification of Acute Leukemia (EGIL) diagnostic criteria - Newly diagnosed disease - Verified by morphology and confirmed by cytochemistry and immunophenotyping - Trephine biopsy is recommended (unless diagnosis can be confirmed by peripheral blood examination) in the event that bone marrow aspiration results in a "dry tap" - Must have MLL gene rearrangements documented by split-signal fluorescence in situ hybridization and meets 1 of the following risk criteria: - Low-risk disease, defined as all MLL germline cases - Medium-risk disease, defined by 1 of the following criteria: - MLL status unknown - MLL rearranged AND age > 6 months - MLL rearranged AND age < 6 months AND WBC < 300 x 10^9/L AND prednisone good response - High-risk disease, defined by MLL rearrangement AND meets the following criteria: - Age at diagnosis < 6 months (i.e., < 183 days) - WBC = 300 x 10^9/L AND/OR prednisone poor response - Minimum donor and stem cell requirements for high-risk patients undergoing stem cell transplantation: - Donor meeting 1 of the following criteria: - HLA-identical sibling - Very well-matched related or unrelated donor - Must be HLA compatible in 10/10 or 9/10 alleles by 4 digit/allele high-resolution molecular genotyping - Stem cell source - Bone marrow (preferred source) OR peripheral blood stem cells of filgrastim [G-CSF]-stimulated donors OR cord blood - Highly-matched unrelated umbilical cord blood (UCB) (> 7/8 matches identified by high-resolution typing) accepted if a sibling donor is not able to donate bone marrow AND UCB with a sufficient number of nucleated cells (NCs) (i.e., > 1.5 x 10^7/kg recipient body weight [BW]) is cryopreserved - Must have = 3 x 10^8 NCs/kg BW OR 3 x 10^6/kg BW CD34-positive cells available for transplantation - CNS or testicular leukemia at diagnosis allowed Exclusion criteria: - Mature B-ALL, defined by the immunophenotypical presence of surface immunoglobulins or t(8;14) and breakpoint as in B-ALL - Presence of the t(9;22) (q34;q11) or bcr-abl fusion in the leukemic cells (if data are not known, patient still may be eligible) - Relapsed ALL PATIENT CHARACTERISTICS: - See Disease Characteristics PRIOR CONCURRENT THERAPY: - More than 4 weeks since prior systemic corticosteroids - Corticosteroids by aerosol are allowed |
Country | Name | City | State |
---|---|---|---|
Austria | St. Anna Children's Hospital | Vienna | |
Belgium | Hopital Universitaire Des Enfants Reine Fabiola | Brussels | |
Czechia | University Hospital Motol | Prague | |
France | CHR Hotel Dieu | Nantes | |
Germany | University Medical Center Hamburg - Eppendorf | Hamburg | |
Germany | Medizinische Hochschule Hannover | Hannover | |
Italy | Nuovo Ospedale San Gerardo at University of Milano-Bicocca | Monza | |
Netherlands | Erasmus MC - Sophia Children's Hospital | Rotterdam | |
United Kingdom | Great Ormond Street Hospital for Children | London | England |
United States | Children's Hospital Boston | Boston | Massachusetts |
United States | M. D. Anderson Cancer Center at University of Texas | Houston | Texas |
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
United States | Children's Hospital and Regional Medical Center - Seattle | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Dutch Childhood Oncology Group | Associazione Italiana Ematologia Oncologia Pediatrica, Australian and New Zealand Children's Oncology Group, BFM Austria, BFM Germany, CLCG France Belgium Portugal, COALL Germany, CORS Monza Italy, CPH, Czech republic, DFCI consortium USA, FRALLE France, Hong Kong, MD Anderson USA, NOPHO Scandinavian countries, PINDA, Chile, PPLLSG Poland, Seattle USA, SJCRH USA, UKCCSG United Kingdom |
United States, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease-free survival | |||
Secondary | Survival | |||
Secondary | Event-free survival | |||
Secondary | Event-free survival within each risk group (i.e., low-risk, medium-risk, or high-risk) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |